Holen Sie sich die Stockscreener-App
1.01
298.58%
0.7566
Handel nachbörslich:
.94
-0.07
-6.93%
Schlusskurs vom Vortag:
$0.2534
Offen:
$0.5232
24-Stunden-Volumen:
352.80M
Relative Volume:
61.96
Marktkapitalisierung:
$13.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+197.06%
1M Leistung:
+157.65%
6M Leistung:
-13.68%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.5112
$1.19
1-Wochen-Bereich:
$0.2472
$1.19
52-Wochen-Spanne:
$0.2472
$4.80
Polyrizon Ltd Stock (PLRZ) Company Profile
Vergleichen Sie PLRZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
1.01 | 13.54M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Polyrizon Ltd Aktie (PLRZ) Neueste Nachrichten
United States shares higher at close of trade; Dow Jones Industrial Average up 1.39% - Investing.com India
Smart Digital Group And Polyrizon See Unusual Market Moves - Finimize
Nasdaq Surges Over 300 Points; Apple Shares Fall After Q2 Results - Benzinga
PLRZ Stock: Exploring Polyrizon Ltd’s Growth - investchronicle.com
Polyrizon (PLRZ) Stock Skyrocketed Over 240% Today: What's Going On? - Benzinga
PLRZ’s price-to-cash ratio: How it affects the stock’s valuation. - uspostnews.com
S&P 500 Gains 1%; April Jobs Top Expectations - Benzinga
Polyrizon Ltd (NASDAQ: PLRZ) Down -12.0% From 52-Week Low; YTD Falls -88.32% – Here’s What To Do Now - Marketing Sentinel
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Polyrizon Ltd. Announces 1-for-10 Reverse Share Split Effective May 5, 2025 - TipRanks
Xylo Technologies: Revoltz Secures First Institutional Client for PORTO EV Logistics Deployment - The Manila Times
Press Release Distribution & PR Platform - ACCESS Newswire
PLRZ’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
How does PLRZ’s price to cash per share ratio compare in the market? - uspostnews.com
Polyrizon advances nasal allergy blocker safety study - Investing.com
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model - The Manila Times
Polyrizon Achieves Milestone with Successful Safety Study of PL-14 - TipRanks
Polyrizon Ltd. Announces Successful Preliminary Safety Study for PL-14 Allergy Blocker Intranasal Hydrogel - Nasdaq
Breakthrough Safety Data: Polyrizon's 4-Hour Nasal Allergy Shield Passes Critical Human Tissue Test - Stock Titan
Polyrizon Ltd. Shareholders Approve Key Amendments at Annual Meeting - TipRanks
Polyrizon receives Nasdaq notification regarding minimum bid requirements - MSN
Polyrizon Faces Nasdaq Compliance Challenge - MSN
Polyrizon Gets Nasdaq Noncompliance Notice Over Minimum Bid Price Rule - marketscreener.com
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements - marketscreener.com
Xylo subsidiary Revoltz launches PORTO EV in Israel - Investing.com Australia
Xylo Technologies: Revoltz Wins 2025 TAIPEI CYCLE Award for Micro-Mobility Innovation - The Manila Times
Polyrizon Raises $17 Million Through Private Placement to Advance Intranasal Hydrogel Technology - citybuzz -
Polyrizon Partners with Branding Firm for Strategic Brand Development - TipRanks
Polyrizon partners with branding firm for hydrogel tech - Investing.com
Polyrizon partners with branding firm for hydrogel tech By Investing.com - Investing.com Australia
Polyrizon Engages Leading Branding Firm for Strategic Brand Development - The Manila Times
Global Launch Preparations: Polyrizon's Game-Changing Virus Protection Technology Takes Major Step Forward - Stock Titan
Polyrizon raises $17 million in private placement By Investing.com - Investing.com South Africa
Polyrizon Ltd. Secures $17 Million in Private Placement to Advance Hydrogel Technology - TipRanks
Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement - The Manila Times
Polyrizon raises $17 million in private placement - Investing.com
Polyrizon Ltd. Announces Closing Of $17.0 Million Private Placement - MarketScreener
$17M Capital Injection: Inside Polyrizon's Latest Private Placement Deal Structure - Stock Titan
Polyrizon secures $17 million in private placement - Investing.com
Polyrizon Ltd. Announces $17.0 Million Private Placement - MarketScreener
Polyrizon Lands Major $17M Financing Deal: Inside the Strategic Investment Terms - Stock Titan
Polyrizon sets clinical strategy for allergy blocker By Investing.com - Investing.com Australia
Polyrizon Prepares Clinical Strategy for Allergy Blocker PL-14 - TipRanks
Polyrizon sets clinical strategy for allergy blocker - Investing.com
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting - The Manila Times
Polyrizon Structures Clinical Strategy For Its Allergy Blocker Ahead Of FDA Pre-Submission Meeting - MarketScreener
Breakthrough Nasal Allergy Treatment Takes Major Step Forward: Inside Polyrizon's FDA Strategy - Stock Titan
Polyrizon Ltd. Announces the Initiation of Preclinical Studies for Intranasal Benzodiazepines - Marketscreener.com
Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment - The Manila Times
Polyrizon begins preclinical studies for seizure treatment By Investing.com - Investing.com South Africa
Polyrizon begins BZDs studies for treating ARS and status epilepticus - TipRanks
Finanzdaten der Polyrizon Ltd-Aktie (PLRZ)
Es liegen keine Finanzdaten für Polyrizon Ltd (PLRZ) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
2.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):